Ingredients by Nature (IBN), a supplier and manufacturer of innovative customisable nutraceutical ingredients, has acquired the Sytrinol brand, including marketing assets associated with the brand such as logos, web domains, human clinicals, patents and marketing data. IBN says it’s committed to providing the level of service and quality brand partners have come to expect.
IBN has manufactured the Sytrinol formula for many years prior to the acquisition. This includes years of experience manufacturing citrus-derived polymethoxylated flavones (PMFs), a key ingredient in the blend of citrus and palm fruit extracts.
Sytrinol provides powerful support for heart health by promoting healthy cholesterol levels, healthy LDL levels with improved LDL:HDL ratio, and healthy triglyceride levels. Research has reportedly shown its positive effects are measurable in as little as 4 weeks. The randomised, double-blind, placebo-controlled research showed a 27% reduction in cholesterol levels, 25% reduction in LDL cholesterol levels, and 31% reduction in triglyceride levels, the company says.
“Having worked with the Sytrinol formulation for a long time, we couldn’t be happier to have this brand underneath our umbrella of citrus-derived ingredients,” said Rob Brewster, president of IBN. “The science speaks for itself that this is among the best available ingredients for heart health, and we look forward to discovering additional ways to innovate with Sytrinol to bring it to an expanded consumer base.”
The company plans to explore the synergistic combination of lemon flavonoid brand Eriomin with Sytrinol. Eriomin is designed to deliver a tri-pronged approach to prediabetes management by helping to address insulin resistance, pro-inflammatory cytokine production and oxidative stress. Excessive blood glucose has been linked to unhealthy cholesterol and triglyceride levels, so by adding Sytrinol’s heart health benefits, the combo may have more potential for prediabetes management and cardiovascular support.
